Russell E Ware

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy
    Russell E Ware
    Duke University Medical Center, Durham, NC 27710, USA
    Blood 99:10-4. 2002
  2. ncbi request reprint Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease
    Sherri A Zimmerman
    Duke Pediatric Sickle Cell Program and Division of Pediatric Hematology Oncology, Duke University Medical Center, PO Box 2916, Durham, NC 27710, USA
    Blood 103:2039-45. 2004
  3. doi request reprint A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia
    Courtney D Thornburg
    Duke Pediatric Sickle Cell Program and Division of Pediatric Hematology Oncology, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Pediatr Blood Cancer 52:609-15. 2009
  4. doi request reprint Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload
    Anthea Greenway
    Department of Pediatrics, Duke University Medical Center, Durham, NC, USA
    Am J Hematol 86:357-61. 2011
  5. ncbi request reprint Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia
    Sherri A Zimmerman
    Duke Pediatric Sickle Cell Program, and Division of Pediatric Hematology Oncology, Duke University Medical Center, Durham, NC, USA
    Blood 110:1043-7. 2007
  6. ncbi request reprint Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy
    Russell E Ware
    Duke Pediatric Sickle Cell Program, Division of Hematology Oncology, Duke University Medical Center, Durham, North Carolina, USA
    J Pediatr 145:346-52. 2004
  7. ncbi request reprint Acute parvovirus B19 infection mimicking congenital dyserythropoietic anemia
    Shannon L Carpenter
    Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Pediatr Hematol Oncol 26:133-5. 2004
  8. ncbi request reprint Enalapril and hydroxyurea therapy for children with sickle nephropathy
    Courtney D Fitzhugh
    Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Pediatr Blood Cancer 45:982-5. 2005
  9. ncbi request reprint Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan
    Jun ichi Nishimura
    PNH Research Committee, Duke University Medical Center, Durham, North Carolina 27710, USA
    Medicine (Baltimore) 83:193-207. 2004
  10. pmc Clinical and hematologic benefits of partial splenectomy for congenital hemolytic anemias in children
    Henry E Rice
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Ann Surg 237:281-8. 2003

Collaborators

Detail Information

Publications38

  1. ncbi request reprint Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy
    Russell E Ware
    Duke University Medical Center, Durham, NC 27710, USA
    Blood 99:10-4. 2002
    ..The HbF response to hydroxyurea is variable and complex, however, and even children with low baseline %HbF values can develop substantial increases in %HbF at MTD...
  2. ncbi request reprint Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease
    Sherri A Zimmerman
    Duke Pediatric Sickle Cell Program and Division of Pediatric Hematology Oncology, Duke University Medical Center, PO Box 2916, Durham, NC 27710, USA
    Blood 103:2039-45. 2004
    ..Long-term hydroxyurea therapy at MTD is well tolerated by pediatric patients with SCD and has sustained hematologic efficacy with apparent long-term safety...
  3. doi request reprint A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia
    Courtney D Thornburg
    Duke Pediatric Sickle Cell Program and Division of Pediatric Hematology Oncology, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Pediatr Blood Cancer 52:609-15. 2009
    ..Hydroxyurea improves laboratory parameters and prevents acute clinical complications of sickle cell anemia (SCA) in children and adults, but its effects on organ function remain incompletely defined...
  4. doi request reprint Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload
    Anthea Greenway
    Department of Pediatrics, Duke University Medical Center, Durham, NC, USA
    Am J Hematol 86:357-61. 2011
    ..Long-term assessments of this therapy should evaluate risk factors for secondary stroke and assessments of hemosiderosis, neurocognitive outcome, and health-related quality of life...
  5. ncbi request reprint Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia
    Sherri A Zimmerman
    Duke Pediatric Sickle Cell Program, and Division of Pediatric Hematology Oncology, Duke University Medical Center, Durham, NC, USA
    Blood 110:1043-7. 2007
    ..A multicenter trial is warranted to determine the efficacy of hydroxyurea for the management of increased TCD values, and ultimately for primary stroke prevention in children with SCA...
  6. ncbi request reprint Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy
    Russell E Ware
    Duke Pediatric Sickle Cell Program, Division of Hematology Oncology, Duke University Medical Center, Durham, North Carolina, USA
    J Pediatr 145:346-52. 2004
    ..Transfusions prevent secondary stroke in children with sickle cell anemia (SCA) but also cause iron overload. Alternatives for stroke prophylaxis with effective therapy to reduce iron burden are needed...
  7. ncbi request reprint Acute parvovirus B19 infection mimicking congenital dyserythropoietic anemia
    Shannon L Carpenter
    Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Pediatr Hematol Oncol 26:133-5. 2004
    ..This case expands the spectrum of hematologic disease associated with acute parvovirus infection...
  8. ncbi request reprint Enalapril and hydroxyurea therapy for children with sickle nephropathy
    Courtney D Fitzhugh
    Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Pediatr Blood Cancer 45:982-5. 2005
    ..Hydroxyurea therapy may further normalize the urine protein/creatinine ratio. Combination therapy should be tested prospectively in children with sickle nephropathy...
  9. ncbi request reprint Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan
    Jun ichi Nishimura
    PNH Research Committee, Duke University Medical Center, Durham, North Carolina 27710, USA
    Medicine (Baltimore) 83:193-207. 2004
    ..These data identify important differences between white and Asian patients with PNH. Identification of prognostic factors will help the design of prospective clinical trials for PNH...
  10. pmc Clinical and hematologic benefits of partial splenectomy for congenital hemolytic anemias in children
    Henry E Rice
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Ann Surg 237:281-8. 2003
    ..To assess the role of partial splenectomy for symptomatic children with various congenital hemolytic anemias...
  11. ncbi request reprint Prevalence of factor V G1691A (Leiden), prothrombin G20210A, and methylene tetrahydrofolate reductase C677T thrombophilic mutations in children with inflammatory bowel disease
    Howard A Kader
    Division of Pediatric GI Nutrition, Department of Pediatrics, Duke University Medical Center, Duke University School of Medicine, Durham, North Carolina 27710, USA
    J Pediatr Gastroenterol Nutr 35:629-35. 2002
    ..3%, 26.6%, respectively), blacks (0.8%, 0.3%, and 12.4%, respectively), and Hispanics (1.2%, 2.4%, and 41.5%, respectively). We sought to determine the prevalence of these thrombophilic mutations in a large cohort of children with IBD...
  12. ncbi request reprint Neurocognitive development of young children with sickle cell disease through three years of age
    Robert J Thompson
    Duke University Medical Center, USA
    J Pediatr Psychol 27:235-44. 2002
    ....
  13. ncbi request reprint Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura
    Kristi L Bengtson
    Division of Pediatric Hematology Oncology, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Pediatr 143:670-3. 2003
    ..We report the efficacy of humanized anti-CD20 monoclonal antibody (rituximab, Rituxan) therapy for an infant with severe, refractory life-threatening immune thrombocytopenic purpura...
  14. ncbi request reprint In vitro induction of fetal hemoglobin in human erythroid progenitor cells
    Janie A Ho
    Division of Pediatric Hematology Oncology, Duke University Medical Center, Durham, NC, USA
    Exp Hematol 31:586-91. 2003
    ..Hydroxyurea, a known S-phase-specific cytotoxic ribonucleotide reductase (RR) inhibitor, is an effective agent for HbF induction in patients with SCA, but the mechanisms by which hydroxyurea induces HbF in vivo have not been elucidated...
  15. ncbi request reprint UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia
    Matthew M Heeney
    Pediatric Sickle Cell Program and Division of Pediatric Hematology Oncology, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA
    J Lab Clin Med 141:279-82. 2003
    ..UGT1A promoter polymorphisms may therefore influence the ability of hydroxyurea to prevent gallstone formation in patients with SCA...
  16. ncbi request reprint Malignancy in patients with sickle cell disease
    William H Schultz
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Hematol 74:249-53. 2003
    ..These data provide essential baseline information for the accurate interpretation of future reports of malignancy in patients with SCD, especially those receiving hydroxyurea therapy...
  17. pmc Impact of hydroxyurea on clinical events in the BABY HUG trial
    Courtney D Thornburg
    Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA
    Blood 120:4304-10; quiz 4448. 2012
    ..This clinical trial is registered with the National Institutes of Health (NCT00006400, www.clinicaltrials.gov)...
  18. ncbi request reprint Short stature in children with sickle cell anemia correlates with alterations in the IGF-I axis
    Paulo F Collett-Solberg
    Rio de Janeiro, Brazil, Department ofPediatrics, Duke University Medical Center, Durham, NC, USA
    J Pediatr Endocrinol Metab 20:211-8. 2007
    ..028). We demonstrated that children with SCA have abnormalities in the IGF-I axis, which worsen with age...
  19. ncbi request reprint Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency
    Matthew M Heeney
    Division of Hematology Oncology, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Pediatr 143:662-5. 2003
    ..Routine screening of immunoglobulins is suggested for children with chronic or recurrent immune thrombocytopenic purpura and autoimmune hemolytic anemia...
  20. ncbi request reprint Subclinical parvovirus B19 infection in children with sickle cell anemia
    Sherri A Zimmerman
    Division of Hematology Oncology, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Pediatr Hematol Oncol 25:387-9. 2003
    ..To investigate the prevalence and clinical consequences of previous parvovirus B19 exposure in a large cohort of pediatric patients with sickle cell anemia (SCA)...
  21. ncbi request reprint Increased expression of anti-apoptosis genes in peripheral blood cells from patients with paroxysmal nocturnal hemoglobinuria
    Matthew M Heeney
    Division of Pediatric Hematology Oncology, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA
    Mol Genet Metab 78:291-4. 2003
    ..Anti-apoptosis gene upregulation may confer resistance to apoptosis in PNH and related disorders, and provide a common compensatory mechanism after bone marrow injury that allows survival and growth of remaining hematopoietic stem cells...
  22. ncbi request reprint Interpretation of fetal hemoglobin only on newborn screening for hemoglobinopathy
    Matthew M Heeney
    Duke University Medical Center, Durham, North Carolina 27710, USA
    J Pediatr Hematol Oncol 24:499-502. 2002
    ..Accurate interpretation of the fetal hemoglobin only result on newborn screening requires thorough evaluation, including family studies and molecular analysis...
  23. doi request reprint Partial splenectomy for children with congenital hemolytic anemia and massive splenomegaly
    Diana L Diesen
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Pediatr Surg 43:466-72. 2008
    ..Partial splenectomy is a safe, effective, and technically feasible option for children with various CHAs, even in the setting of massive splenomegaly...
  24. ncbi request reprint Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab)
    Heidi H Kong
    Division of Dermatology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Pediatr Dermatol 22:461-4. 2005
    ..She had a corresponding decline in circulating antibodies against desmoglein 1 and 3 and a decline in diphtheria and tetanus-specific antibody titers...
  25. ncbi request reprint Asymmetrical closure of epiphyses in a patient with sickle cell anemia
    Paulo F Collett-Solberg
    Division of Endocrinology, Duke University Medical Center, Durham, NC, USA
    J Pediatr Endocrinol Metab 15:1207-12. 2002
    ..Children with SCA should always have their arm span measured carefully...
  26. doi request reprint UGT1A1 promoter polymorphisms and the development of hyperbilirubinemia and gallbladder disease in children with sickle cell anemia
    Shannon L Carpenter
    Division of Hematology Oncology, Department of Pediatrics, University of Texas Health Science Center, San Antonio, Texas 78207, USA
    Am J Hematol 83:800-3. 2008
    ..UGT1A1 genotyping should be considered as a screening tool for predicting children most likely to develop gallbladder disease at a young age...
  27. doi request reprint Chemical and functional analysis of generic hydroxyurea formulations
    Virginia L Harrod
    Department of Hematology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Pediatr Hematol Oncol 25:423-9. 2008
    ..Generic hydroxyurea formulations represent a potent yet inexpensive therapeutic option for children with SCA worldwide...
  28. doi request reprint Hydroxyurea for children with sickle cell disease
    Matthew M Heeney
    Harvard Medical School, Boston, MA, USA
    Pediatr Clin North Am 55:483-501, x. 2008
    ..Although clinical trials are underway to address long-term issues, hydroxyurea remains an effective but underutilized therapy for SCD...
  29. ncbi request reprint Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study
    Winfred C Wang
    Hematology Division, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    J Pediatr 140:225-9. 2002
    ..We report the growth characteristics of patients in the Phase I-II pediatric hydroxyurea trial (HUG-KIDS) before and during treatment at the maximum tolerated dose for one year...
  30. ncbi request reprint Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea
    Jane S Hankins
    Department of Hematology, Comprehensive Sickle Cell Center, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 50:293-7. 2008
    ..Chronic organ damage is an insidious process in patients with sickle cell anemia (SCA). Although hydroxyurea prevents acute vaso-occlusive events, its effects on the preservation of organ function remain undefined...
  31. ncbi request reprint Identification of hemochromatosis gene polymorphisms in chronically transfused patients with sickle cell disease
    Michael R Jeng
    Department of Pediatrics, Stanford University School of Medicine, Stanford, California 94305, USA
    Am J Hematol 74:243-8. 2003
    ..We conclude that the presence of recognized HFE coding region mutations do not seem to have an impact on the degree of iron overload in patients with SCD receiving chronic transfusion therapy...
  32. ncbi request reprint Quantitative analysis of Howell-Jolly bodies in children with sickle cell disease
    Virginia L Harrod
    Department of Hematology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Exp Hematol 35:179-83. 2007
    ..Analysis of these cell populations allows quantitative measurement of splenic filtrative function and possible chromosomal damage...
  33. pmc Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study
    Jane S Hankins
    St Jude Comprehensive Sickle Cell Center, Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Blood 106:2269-75. 2005
    ..Infants with SCA tolerate prolonged hydroxyurea therapy with sustained hematologic benefits, fewer ACS events, improved growth, and possibly preserved organ function...
  34. ncbi request reprint Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell disease
    Deborah Dean
    Children s Hospital Oakland Research Institute, 5700 Martin Luther King Jr Way, Oakland, CA 94609, USA
    J Pediatr Hematol Oncol 25:46-55. 2003
    ..The purpose of this study was to analyze the clinical course and outcome of C. pneumoniae-associated ACS among SCD patients as part of the National Acute Chest Syndrome Study...
  35. ncbi request reprint Hydroxyurea therapy for management of secondary erythrocytosis in cyanotic congenital heart disease
    Ulrike M Reiss
    Department of Hematology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Am J Hematol 82:740-3. 2007
    ..Hydroyxurea provides a novel and useful therapeutic approach to reduce hyperviscosity from secondary erythrocytosis in patients with CCHD, while preserving oxygen carrying capacity and avoiding iron depletion by phlebotomy...
  36. ncbi request reprint Beta-thalassemia intermedia due to compound heterozygosity for two beta-globin gene promoter mutations, including a novel TATA box deletion
    Raveen K Basran
    Hemoglobin Diagnostic Reference Laboratory, Boston Medical Center, Boston, Massachusetts, USA
    Pediatr Blood Cancer 50:363-6. 2008
    ..His mother and 14-year-old brother were simple heterozygotes for this novel (AA) deletion. Both heterozygotes had normal Hb level, borderline microcytosis, and elevated Hb A(2)...
  37. ncbi request reprint Hemoglobinopathies mimicking Hb S/beta-thalassemia: Hb S/S with alpha-thalassemia and Hb S/Volga
    Hong Yuan Luo
    Hemoglobin Diagnostic Reference Laboratory, Boston Medical Center, Boston, Massachusetts 02118, USA
    Am J Hematol 81:361-5. 2006
    ..These studies underscore the importance to correlate clinical course with laboratory diagnosis and to make DNA-based diagnostics more widely available for patients with unusual or complicated hemoglobin disorders...
  38. ncbi request reprint Chemical and functional analysis of hydroxyurea oral solutions
    Matthew M Heeney
    Division of Pediatric Hematology Oncology, Children s Hospital Boston, 300 Longwood Avenue, Boston, MA 02115 5724, USA
    J Pediatr Hematol Oncol 26:179-84. 2004
    ..Hydroxyurea oral solutions prepared and dispensed monthly are suitable for use in the upcoming infant BABY HUG trial...